Chondroitin-based supplements from Zeria Pharmaceutical launched to promote an active lifestyle SINGAPORE, April 23, 2024 /PRNewswire/ Borsch Med Pte Ltd (BM), a leading Traditional Chinese Medicine (TCM), Health and Nutrition company based in Singapore, operated and managed by professionals in Goh Joo Hin Pte Ltd (GJH), announces its appointment as the authorised distributor for Zeria Pharmaceutical Co..
Kidney Disease Market Size & Forecast to 2027 - COVID-19 Impact and Global Analysis by Product Type (Diagnosis, Treatment); End User (Hospital, Diagnostic
Award-winning market research Company has published a report on the global X-linked hypophosphatemia market. The interest for x-linked hypophosphatemia will, in general, be affected by a few elements, going from genetic diseases rate to the spending on medical care administrations. Furthermore, useful procedures for.
DIFICLIRTM (fidaxomicin) is now recommended as first-line CDI treatment in both European and U.S. guidelines1,2 Significantly fewer patients in the fidaxomicin group than the vancomycin group
Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth1
DEMAND INFLUENCED BY LOCKDOWN MEASURES
Global in-market sales: CHF 1,005 million, up 0.1% and 49.5% share in the i.v. iron segment of the iron market
4 by value in 2020
5
Net sales of CHF 552.2 million, a decrease of 1.6%, an increase of 3.0% at CER.
Improvements in Q3 in line with the easing of COVID-19 restrictions and better patient access to infusions, followed by a slowdown towards year end as many countries started reintroducing restrictions. Overall utilization of i.v. iron has been highly correlated with intensity of lockdown measures, with recovery to pre-COVID-19 growth levels expected once COVID-19 restrictions are lifted.